Chinese MedicineInnovation power has ushered in a historic breakthrough in Africa. On July 25, 2025, Jiangsu Aidea PharmaceuticalThe innovative anti-HIV drug independently developed by Aidea PharmaceuticalsThe New Drug Application (NDA) of Fubond® (generic name: Enomitid tablets) has been officially approved by the Zanzibar Food and Drug Administration (ZFDA). This not only marks the successful launch of Aidea Pharmaceuticals' first innovative drug , but also means that China's independently developed new anti-AIDS drug has taken root in Africa for the first time, setting a key milestone for China's pharmaceutical industry to participate in solving major global public health challenges.

Focusing on Africa's urgent needs, the Chinese solution is moving forward. Africa bears the arduous challenge of the global fight against AIDS. According to statistics, about 70% of the world's AIDS patients (more than 26 million people) live on this continent. The approval of Fubond® in Zanzibar (a part of the United Republic of Tanzania in Africa) has opened up a direct channel for China's innovative drugs to benefit the people who need them most, and provided a new "Chinese solution" to improve the accessibility and effectiveness of AIDS treatment in Africa.

Six major clinical advantages build a solid line of defense against AIDS. Fubond® has been recognized for its good comprehensive clinical value. Confirmed efficacy, safety benefits: With solid evidence of effectiveness, it demonstrates its advantages in treatment safety; immune reconstruction, no worries about drug resistance: Promotes friendly reconstruction of the patient's immune system, low risk of drug resistance, and reduced incidence of drug resistance; Improved compliance, universal access: Optimized treatment plans improve patients' long-term medication compliance, and lays the foundation for widespread popularization with affordable prices.

Empowering enterprises to take off and charting a "global road" for Chinese medicine. This approval is of great significance to the internationalization strategy and long-term development of Aidea Pharmaceuticals. It is not only a strong proof of the company's innovative strength, but also a key step for it to enter the global market, especially the emerging markets with huge demand. For the field of Chinese anti-AIDS drug research and development, the successful overseas launch of Fubond® is also a shot in the arm, demonstrating the huge potential and responsibility of China's original innovative drugs to participate in international competition and serve global patients.

"The launch of Fubond® in Zanzibar is a vivid practice of our dream of 'making Chinese medicine good and taking a good global path'," said Fu Heliang, Chairman of Aidea Pharmaceuticals. "This is just the beginning. We will use this as a cornerstone to accelerate the registration and access of the drug in more African countries, and strive to bring high-quality and affordable Chinese innovative therapies to people living with HIV/AIDS around the world, and contribute solid Chinese scientific and technological strength to ending the public health threat of AIDS."

Source：https://finance.eastmoney.com/a/202507283468580517.html